1

JectasInnovators Co., Ltd.
VACCINES, ADJUVANTS, MONOCLONAL ANTIBODIES,PROTEIN ENGINEERING, MOLECULAR DESIGN

2“

Jectas Innovators isyour partner of choicefor development ofinnovative vaccines
and to open up its
future.

”3

Our Strengths

Strengths in early-stage
vaccine development
Jectas Innovators focuses on research anddevelopment of veterinary vaccines against
infectious diseases.

Our strengths are in bioengineering techniques forprotein design and recombinant protein expression
as well as in biochemical and immunologicalanalyses of proteins. Those techniques are
particularly important during the early stages ofvaccine development. Since our establishment, wehave been working intimately with pharmaceuticalcompanies to achieve our goals. Our unique andproprietary protein design technologies haveallowed us to develop vaccines against livestock
diseases such as porcine edema disease andchicken egg drop syndrome4

Devoted to subunit
vaccine development


Most prophylactic vaccines against veterinary
infectious diseases are composed of liveattenuated or killed pathogens or purified toxoids.

We focus instead on protein antigens ofpathogen origin that are critical for their survival
and multiplication in the body. Throughappropriate selection of pathogen-derived
antigens, application of our unique protein design
and modification technologies, and exploitationof various recombinant protein expression systems(e.g., Escherichia coli, yeast and silkworm), we
create subunit vaccine molecules that are safer
and more effective than ever before.

5

6

Research andDevelopment

Infectious diseasevaccine projects

Our company's most important mission is todevelop recombinant protein-based veterinary
vaccines against infectious diseases of pigs,
chickens and other domestic animals. Unlike
conventional live-attenuated or killed vaccines,
we genetically engineer recombinant protein
vaccines using our original and unique protein
design technologies.

Examples include a vaccine for preventing
porcine edema disease (US 9,701,724 B2) and aprophylactic vaccine against egg drop syndrome(WO2015163037).

7

Adjuvant projects
Adjuvants are immune potentiators, and areessential components of recombinant protein
vaccines used to augment their immunogenicities.
However, adjuvants approved for clinical use arevery limited.

We are searching for new compounds with thepotential to be developed as vaccine adjuvants
from large repertoires of bioresources derived
from plants, animals and microorganisms both onland and in the sea. We also evaluate theadjuvant effects of various known chemicalcompounds.

8

Therapeutic antibody
projects
Several of our projects focus on the developmentof therapeutic monoclonal antibodies. Since
monoclonal antibodies specifically recognize andbind to a single unique epitope of pathogen- ortoxin-derived antigen, they are generally
considered safer than antisera derived fromanimals such as horses, which contain a mixture ofvarious types of antibodies (i.e., polyclonalantibodies). Thus, monoclonal antibodies arehighly useful for therapies against many kinds ofdiseases.

We are particularly interested in development of
toxin-neutralizing monoclonal antibodies against
bacterial protein toxins and snake venoms.

9

Diagnostic tool projects
In these projects we develop diagnostic tools
based on immunological techniques such as
immunochromatography (ICT) or enzyme-linked
immunosorbent assay (ELISA). We are particularlyinterested in development of ICT test kits for
infectious diseases of domestic animals, including
companion animals like dogs and cats. These test
kits are designed to achieve rapid andconvenient diagnosis, and thus are useful in small
veterinary hospitals and even in the field.

We also develop ICT kits for detecting snake
venoms, which could provide useful information intreating patients bitten by unidentified snakes.

10

Contact usJectas Innovators Co., Ltd.
Headquarters:
1-29-15 Tsuboya, Naha, Okinawa 902-0065, Japan
Laboratories:
1 Senbaru, Nishihara, Okinawa 903-0213, Japan
Phone: +81-98-895-8943
Fax: +81-98-895-8944
E-mail: tarakawa@jectasinnovators.com
https://jectasinnovators.com

11